WO2002078612A3 - Anticorps synthetique contenant de la thrombopoietine (tpo) pour la stimulation de la production de plaquettes - Google Patents

Anticorps synthetique contenant de la thrombopoietine (tpo) pour la stimulation de la production de plaquettes Download PDF

Info

Publication number
WO2002078612A3
WO2002078612A3 PCT/US2002/010301 US0210301W WO02078612A3 WO 2002078612 A3 WO2002078612 A3 WO 2002078612A3 US 0210301 W US0210301 W US 0210301W WO 02078612 A3 WO02078612 A3 WO 02078612A3
Authority
WO
WIPO (PCT)
Prior art keywords
thrombopoietin
synthebody
stimulation
tpo
platelet production
Prior art date
Application number
PCT/US2002/010301
Other languages
English (en)
Other versions
WO2002078612A2 (fr
Inventor
Daniel A Soltis
Ronald M Burch
Robert A Ogert
Original Assignee
Purdue Pharma Lp
Daniel A Soltis
Ronald M Burch
Robert A Ogert
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Pharma Lp, Daniel A Soltis, Ronald M Burch, Robert A Ogert filed Critical Purdue Pharma Lp
Priority to AU2002307062A priority Critical patent/AU2002307062A1/en
Priority to US10/469,124 priority patent/US20040136980A1/en
Publication of WO2002078612A2 publication Critical patent/WO2002078612A2/fr
Publication of WO2002078612A3 publication Critical patent/WO2002078612A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne une région variable synthétique d'une construction d'immunoglobuline qui contient, dans au moins une de ses CDR, une séquence de thrombopoïétine, par exemple, IEGPTLRQWLAARA, ou ses dérivés. Cette construction peut fixer et activer efficacement un récepteur de thrombopoïétine (MPL) provoquant la stimulation de la prolifération, la croissance ou la différenciation ou bien la modulation de l'apoptose des cellules hématopoïétiques, en particulier des cellules progénitrices de plaquettes. L'invention concerne en outre l'utilisation de l'anticorps de synthèse pour le traitement de troubles hématopoïétiques ou immunitaires, et en particulier de la thrombocytopénie résultant de la chimiothérapie, de la radiothérapie ou de la transfusion de moelle osseuse.
PCT/US2002/010301 2001-04-02 2002-04-02 Anticorps synthetique contenant de la thrombopoietine (tpo) pour la stimulation de la production de plaquettes WO2002078612A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2002307062A AU2002307062A1 (en) 2001-04-02 2002-04-02 Thrombopoietin (tpo) synthebody for stimulation of platelet production
US10/469,124 US20040136980A1 (en) 2002-04-02 2002-04-02 Thrombopoietin(tpo) synthebody for stimulation of platelet production

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28118301P 2001-04-02 2001-04-02
US60/281,183 2001-04-02

Publications (2)

Publication Number Publication Date
WO2002078612A2 WO2002078612A2 (fr) 2002-10-10
WO2002078612A3 true WO2002078612A3 (fr) 2003-04-03

Family

ID=23076287

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/010301 WO2002078612A2 (fr) 2001-04-02 2002-04-02 Anticorps synthetique contenant de la thrombopoietine (tpo) pour la stimulation de la production de plaquettes

Country Status (2)

Country Link
AU (1) AU2002307062A1 (fr)
WO (1) WO2002078612A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8945543B2 (en) 2005-06-10 2015-02-03 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
US9241994B2 (en) 2005-06-10 2016-01-26 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical compositions containing sc(Fv)2
US9493569B2 (en) 2005-03-31 2016-11-15 Chugai Seiyaku Kabushiki Kaisha Structural isomers of sc(Fv)2

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7531643B2 (en) 1997-09-11 2009-05-12 Chugai Seiyaku Kabushiki Kaisha Monoclonal antibody inducing apoptosis
AU773891C (en) 1998-10-23 2005-02-17 Kirin-Amgen Inc. Dimeric thrombopoietin peptide mimetics binding to MP1 receptor and having thrombopoietic activity
KR100870123B1 (ko) * 2000-10-20 2008-11-25 츄가이 세이야꾸 가부시키가이샤 저분자화 아고니스트 항체
AU2002210917B2 (en) * 2000-10-20 2006-05-18 Chugai Seiyaku Kabushiki Kaisha Degraded TPO agonist antibody
EP1327681A4 (fr) * 2000-10-20 2004-09-01 Chugai Pharmaceutical Co Ltd Anticorps agoniste degrade
US7396917B2 (en) 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
EP1642910B1 (fr) * 2000-12-05 2012-02-08 Alexion Pharmaceuticals, Inc. Anticorps conçus de manière rationnelle
AU2003295623B2 (en) * 2000-12-05 2008-06-05 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
US7332474B2 (en) * 2001-10-11 2008-02-19 Amgen Inc. Peptides and related compounds having thrombopoietic activity
EP1499346B1 (fr) * 2002-04-09 2008-01-02 The Curators Of The University Of Missouri Traitement du diabete de type 1 avant et apres l'expression de marqueurs de predisposition
NZ566812A (en) * 2002-09-18 2009-07-31 Ortho Mcneil Pharm Inc Methods of increasing platelet and hematopoietic stem cell production
JP2004279086A (ja) 2003-03-13 2004-10-07 Konica Minolta Holdings Inc 放射線画像変換パネル及び放射線画像変換パネルの製造方法
US20070105824A1 (en) * 2003-04-29 2007-05-10 Erickson-Miller Connie L Methods for treating degenerative diseases/injuries
US7723295B2 (en) 2003-08-28 2010-05-25 Ortho-Mcneil Pharmaceutical, Inc. Peptides and compounds that bind to a receptor
US7576056B2 (en) 2003-08-28 2009-08-18 Ortho-Mcneil Pharmaceutical, Inc. Peptides and compounds that bind to a receptor
WO2005021595A1 (fr) * 2003-08-28 2005-03-10 Euro-Celtique S.A. Procedes utilisant les regles des regions de presentation des anticorps pour intervenir sur des anticorps
TW200530269A (en) * 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Anti-Mpl antibodies
EP3623473A1 (fr) 2005-03-31 2020-03-18 Chugai Seiyaku Kabushiki Kaisha Procédé pour la production de polypeptide au moyen de la régulation d'un ensemble
AU2007208226A1 (en) * 2006-01-25 2007-08-02 Amgen Inc. Thrombopoietic compounds
US9670269B2 (en) 2006-03-31 2017-06-06 Chugai Seiyaku Kabushiki Kaisha Methods of modifying antibodies for purification of bispecific antibodies
US20140047572A1 (en) * 2012-08-13 2014-02-13 University Of Rochester Thrombopoietin mimetics for the treatment of radiation or chemical induced bone marrow injury
DK3050896T3 (da) 2013-09-27 2021-07-19 Chugai Pharmaceutical Co Ltd Fremgangsmåde til fremstilling af en polypeptid-heteromultimer
JP7219005B2 (ja) 2015-12-28 2023-02-07 中外製薬株式会社 Ｆｃ領域含有ポリペプチドの精製を効率化するための方法
EP3553079A1 (fr) * 2018-04-12 2019-10-16 Bayer Aktiengesellschaft Anticorps greffés de peptide natriurétique de type c
EP3553081A1 (fr) * 2018-04-12 2019-10-16 Bayer Aktiengesellschaft Anticorps greffés de peptide natriurétique auriculaire
EP3553082A1 (fr) * 2018-04-12 2019-10-16 Bayer Aktiengesellschaft Anticorps greffés de peptide natriurétique du cerveau

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5658762A (en) * 1989-02-24 1997-08-19 Zanetti; Maurizio DNA molecules, expression vectors and host cells expressing antigenized antibodies
US6083913A (en) * 1995-06-07 2000-07-04 Glaxo Wellcome Inc. Peptides and compounds that bind to a thrombopoietin receptor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5658762A (en) * 1989-02-24 1997-08-19 Zanetti; Maurizio DNA molecules, expression vectors and host cells expressing antigenized antibodies
US6083913A (en) * 1995-06-07 2000-07-04 Glaxo Wellcome Inc. Peptides and compounds that bind to a thrombopoietin receptor

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9493569B2 (en) 2005-03-31 2016-11-15 Chugai Seiyaku Kabushiki Kaisha Structural isomers of sc(Fv)2
US8945543B2 (en) 2005-06-10 2015-02-03 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
US9241994B2 (en) 2005-06-10 2016-01-26 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical compositions containing sc(Fv)2

Also Published As

Publication number Publication date
AU2002307062A1 (en) 2002-10-15
WO2002078612A2 (fr) 2002-10-10

Similar Documents

Publication Publication Date Title
WO2002078612A3 (fr) Anticorps synthetique contenant de la thrombopoietine (tpo) pour la stimulation de la production de plaquettes
WO1998025965A3 (fr) Peptides et composes qui se lient a un recepteur
AP1918A (en) Antibodies to CD40
MX9709315A (es) Peptidos y compuestos que se unen a un receptor de trombopoyetina.
AU2003215188A1 (en) Fusion proteins of humanized g250 specific antibodies and uses thereof
WO2004029093A3 (fr) Anticorps anti-granulocytes chimeres, humains et humainises
WO2007058823A3 (fr) Anticorps anti-egfr
SG10201407388XA (en) Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
MY147019A (en) Anti-alpha v beta 6 antibodies
MY157376A (en) Antibodies to m-csf
AU2001258567A1 (en) Humanised antibodies to the epidermal growth factor receptor
MX9602971A (es) Anticuerpos humanizados contra la molecula vla-4 de adhesion de leucocitos.
WO2011109789A3 (fr) Compositions et procédés pour des anticorps et protéines de fusion immunomodulateurs ciblés
HK1044159A1 (zh) 抗γ-干擾素的人化抗體
WO2004028454A3 (fr) 1, 3, 5-triazines destinees au traitement de maladies virales
AU2003295326A1 (en) Cancer therapy using beta glucan and antibodies
MY113497A (en) Peptides and compounds that bind to a receptor
WO2005062977A3 (fr) Anticorps humains d'internalisation specifiques du cancer de la prostate
SI1432737T1 (sl) Humano mini-protitelo, citotoksično za tumorske celice, ki izražajo ERBB2 receptor
WO2004080425A3 (fr) Composes polypeptidiques permettant d'inhiber l'angiogenese et la croissance tumorale
Steinbacher et al. An Fc‐optimized NKG2D‐immunoglobulin G fusion protein for induction of natural killer cell reactivity against leukemia
WO2006029220A3 (fr) Therapie combinee utilisant des anticorps anti-ctla4 et anti-4-1bb
WO2005023302A3 (fr) Traitement de troubles oculaires
WO2004055513A3 (fr) Utilisation d'antagonistes de cd137 pour le traitement de tumeurs
WO2004099388A3 (fr) Complexes de polypeptides cbl-b et methodes associees

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 10469124

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP